Published in Gut on January 15, 2013
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut (2014) 2.33
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol (2015) 1.67
Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol (2014) 1.04
Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol (2013) 0.99
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog (2014) 0.98
Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers. Gastroenterology (2013) 0.94
Sofosbuvir and ABT-450: terminator of hepatitis C virus? World J Gastroenterol (2013) 0.90
Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy. J Virol (2014) 0.84
Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. J Med Chem (2013) 0.81
Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses (2016) 0.80
Proteomic approaches to analyzing hepatitis C virus biology. Proteomics (2015) 0.75
Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J Viral Hepat (2016) 0.75
Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Non-Macrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease. Antimicrob Agents Chemother (2016) 0.75
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc (2006) 5.42
Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med (2002) 5.30
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J (2002) 4.13
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis (2012) 3.91
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
A role for small RNAs in DNA double-strand break repair. Cell (2012) 3.15
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol (2007) 3.14
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation (2003) 2.69
Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization. Gastrointest Endosc (2007) 2.62
Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol (2007) 2.59
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J (2004) 2.50
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol (2004) 2.47
Transgenic silkworms produce recombinant human type III procollagen in cocoons. Nat Biotechnol (2002) 2.42
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis (2012) 2.41
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol (2012) 2.34
Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J (2003) 2.30
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology (2012) 2.29
Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol (2005) 2.26
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol (2012) 2.24
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
True versus reported waiting times for valvular aortic stenosis surgery. Can J Cardiol (2006) 2.21
Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer (2010) 2.20
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Clinical features of pharyngeal intraepithelial neoplasias and outcomes of treatment by endoscopic submucosal dissection. Gastrointest Endosc (2012) 2.12
Significant improvement in short-term mortality in women undergoing coronary artery bypass surgery (1991 to 2004). J Am Coll Cardiol (2007) 2.11
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet (2011) 2.09
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet (2005) 2.08
Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc (2007) 2.04
AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood (2008) 2.03
Genetic polymorphisms and esophageal cancer risk. Int J Cancer (2007) 2.02
A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet (2011) 1.96
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Narrow-band imaging magnification predicts the histology and invasion depth of colorectal tumors. Gastrointest Endosc (2009) 1.92
Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci (2006) 1.90
Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet (2010) 1.90
Optical biopsy of GI lesions by reflectance-type laser-scanning confocal microscopy. Gastrointest Endosc (2007) 1.87
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut (2010) 1.85
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
G to A hypermutation of hepatitis B virus. Hepatology (2005) 1.83
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood (2003) 1.80
Clinicopathologic features and endoscopic resection of early primary nonampullary duodenal carcinoma. J Clin Gastroenterol (2003) 1.76
RNF5, a RING finger protein that regulates cell motility by targeting paxillin ubiquitination and altered localization. Mol Cell Biol (2003) 1.75
Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol (2004) 1.74
Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: causes and treatment. World J Surg (2007) 1.73
A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J (2003) 1.72
Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol (2012) 1.72
Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection. J Gastroenterol (2008) 1.71
Risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal neoplasms. Int J Colorectal Dis (2014) 1.70
Improved visibility of lesions of the small intestine via capsule endoscopy with computed virtual chromoendoscopy. Gastrointest Endosc (2011) 1.67
Multiple carcinoid tumors of the ileum preoperatively diagnosed by enteroscopy with the double-balloon technique. Gastrointest Endosc (2005) 1.67
Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest (2009) 1.65